G
Gabriele Magliano
Researcher at Catholic University of the Sacred Heart
Publications - 10
Citations - 37
Gabriele Magliano is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 2 publications receiving 3 citations.
Papers
More filters
Journal ArticleDOI
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Maria Stefania Infante,Jon Salmanton-García,Ana Fernández-Cruz,Francesco Marchesi,Ozren Jakšić,Barbora Weinbergerova,Caroline Besson,Rafael F. Duarte,F. Itri,Toni Valković,Tomáš Szotkovski,Alessandro Busca,Anna Guidetti,Andreas Glenthøj,Graham P. Collins,V. Bonuomo,Uluhan Sili,Guldane Cengiz Seval,Marina Machado,Raul Cordoba,Ola Blennow,Ghaith Abu-Zeinah,Sylvain Lamure,Austin G. Kulasekararaj,Iker Falces-Romero,Chiara Cattaneo,Jaap van Doesum,Klára Piukovics,Ali S. Omrani,Gabriele Magliano,Marie-Pierre Ledoux,Cristina de Ramón,Alba Cabirta,Luisa Verga,Alberto Lopez-Garcia,Maria Gomes da Silva,Zlate Stojanoski,Stef Meers,Tobias Lahmer,Sonia Martín Pérez,Julio Dávila-Vals,Jens Van Praet,Michail Samarkos,Yavuz M. Bilgin,Linda Karlsson,Josip Batinic,Anna Nordlander,Martin Schönlein,Martin Hoenigl,Zdenek Racil,Miloš Mladenović,Michaela Hanakova,Giovanni Zambrotta,N. D. de Jonge,Tatjana Adzic-Vukicevic,Raquel Nunes-Rodrigues,Lucia Prezioso,Milan Navrátil,Monia Marchetti,Annarosa Cuccaro,María Calbacho,Antonio Giordano,Oliver A. Cornely,Jose Angel Hernandez-Rivas,Livio Pagano +64 more
TL;DR: Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021, but results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Journal ArticleDOI
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives
TL;DR: Low-intensity conditioning and non-myeloablative conditioning regimens have been designed and have led to improved outcomes in this older patient population and new targeted agents, such as Flt3 inhibitors, are currently being used to improve the control of AML.
Journal ArticleDOI
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Francesco Marchesi,Jon Salmanton-García,Ziad Emarah,Klára Piukovics,Marcio Nucci,Alberto Lopez-Garcia,Zdenek Racil,Francesca Farina,M. Popova,Sofia Zompi,Ernesta Audisio,Marie-Pierre Ledoux,Luisa Verga,Barbora Weinbergerova,Tomáš Szotkowski,Maria Elisa de Souza e Silva,Nicola Stefano Fracchiolla,N. De Jonge,Graham P. Collins,Monia Marchetti,Gabriele Magliano,Carolina Garcia-Vidal,Monika Biernat,J.H. van Doesum,Marina Machado,Fatih Demirkan,Murtadha Al Khabori,Pavel Zak,Benjamin Visek,Igor Stoma,Gustavo Mendez,Johan Maertens,Nina Khanna,Ildefonso Espigado,Giulia Dragonetti,Luana Fianchi,Maria Ilaria Del Principe,Alba Cabirta,Irati Ormazabal-Vélez,Ozren Jakšić,Caterina Buquicchio,V. Bonuomo,Josip Batinic,Ali S. Omrani,Sylvain Lamure,Olimpia Finizio,Noemi Fernandez,Iker Falces-Romero,Ola Blennow,Rui Bergantim,Natasha Ali,Sein Win,Jens Van Praet,Maria Chiara Tisi,A Shirinova,Martin Schönlein,Juergen Prattes,Monica Piedimonte,Verena Petzer,Milan Navrátil,Austin G. Kulasekararaj,Pavel Jindra,Jiri,Andreas Glenthøj,Rita Fazzi,Cristina de Ramón,Chiara Cattaneo,María Calbacho,Nathan C. Bahr,Shaimaa Saber EL-ASHWL,Raul Cordoba,Michaela Hanakova,Giovanni Zambrotta,Mariarita Sciumè,Stephen Booth,Raquel Nunes-Rodrigues,M. Sacchi,Nicole Garcia-Pouton,Juan-Alberto Martín-González,S. N. Khostelidi,Stefanie Katharina Gräfe,Laman Rahimli,Alessandro Busca,Paolo Corradini,Martin Hoenigl,Nikolay Klimko,Philipp Koehler,Antonio Pagliuca,Francesco Passamonti,Oliver A. Cornely,Livio Pagano +90 more
TL;DR: In this paper , the optimal management of AML patients with COVID-19 has not been established, and the best approach to improve survival was to delay AML treatment whenever possible.
Journal ArticleDOI
Severe CMV Infection after Chemo-Immunotherapy with Dose-Reduced Bendamustine and Rituximab in a Mantle Cell Lymphoma Old Patient
Journal ArticleDOI
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Alessandro Busca,Jon Salmanton-García,Francesco Marchesi,Francesca Farina,Guldane Cengiz Seval,Jaap van Doesum,N. D. de Jonge,Nathan C. Bahr,Johan Maertens,Joseph Meletiadis,Nicola Stefano Fracchiolla,Barbora Weinbergerova,Luisa Verga,Zdenek Racil,Moraima Jiménez,Andreas Glenthøj,Ola Blennow,Alina Tanase,Martin Schönlein,Lucia Prezioso,Nina Khanna,Rafael F. Duarte,Pavel Zak,Marcio Nucci,Marina Machado,Austin G. Kulasekararaj,Ildefonso Espigado,Elizabeth de Kort,José-María Ribera-Santa Susana,Monia Marchetti,Gabriele Magliano,Iker Falces-Romero,Osman Ilhan,Emanuele Ammatuna,Sofia Zompi,Panagiotis Tsirigotis,Anastasia Antoniadou,Giovanni Zambrotta,Anna Nordlander,Linda Karlsson,Michaela Hanakova,Giulia Dragonetti,Alba Cabirta,Caroline Berg Venemyr,Stefanie Katharina Gräfe,Jens Van Praet,Athanasios Tragiannidis,Verena Petzer,Alberto Lopez-Garcia,F. Itri,A. Groh,Eleni Gavriilaki,Michelina Dargenio,Laman Rahimli,Oliver A. Cornely,Livio Pagano +55 more
TL;DR: In this paper , the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT were retrospectively analyzed.